UK markets close in 4 hours 36 minutes
  • FTSE 100

    7,753.28
    -11.87 (-0.15%)
     
  • FTSE 250

    19,803.27
    -232.12 (-1.16%)
     
  • AIM

    865.79
    -3.45 (-0.40%)
     
  • GBP/EUR

    1.1365
    -0.0039 (-0.34%)
     
  • GBP/USD

    1.2381
    -0.0014 (-0.12%)
     
  • BTC-GBP

    18,690.71
    -301.24 (-1.59%)
     
  • CMC Crypto 200

    523.77
    +6.77 (+1.31%)
     
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • DOW

    33,978.08
    +28.68 (+0.08%)
     
  • CRUDE OIL

    79.66
    -0.02 (-0.03%)
     
  • GOLD FUTURES

    1,939.70
    -5.90 (-0.30%)
     
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • HANG SENG

    22,069.73
    -619.17 (-2.73%)
     
  • DAX

    15,001.70
    -148.33 (-0.98%)
     
  • CAC 40

    7,035.24
    -61.97 (-0.87%)
     

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

ReportLinker
ReportLinker

Summary. This reports provides a data-driven overview of the current and future competitive landscape in CIDP therapeutics. Synopsis. - In 2022, there will be more than 180,000 diagnosed prevalent cases of CIDP across 16 pharmaceutical markets.

New York, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06383001/?utm_source=GNW


Summary
This reports provides a data-driven overview of the current and future competitive landscape in CIDP therapeutics.

Synopsis
- In 2022, there will be more than 180,000 diagnosed prevalent cases of CIDP across 16 pharmaceutical markets.
- The majority of marketed drugs for the treatment of CIDP fall into the human immunoglobulins category.
- There are only six drugs in Phase III pipeline for CIDP.
- Commercial sponsors dominate clinical trial development in CIDP, with Europe emerging as the key region for conducting Phase III trials in CIDP.
- In deals involving companies developing CIDP assets, four strategic alliances were successfully completed.
- During the next 18 months, only one drug is expected to enter the US and the EU markets.

Scope
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CIDP market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CIDP market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06383001/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001